Table 5.
Expense for both actual treatment with dalbavancin and hypothetical continuation of in-hospital standard treatment
| Variables | Total (n = 50) | ABSSSIs (n = 12) | Complicated ABSSSIs (n = 8) | Bone and joints infections (n = 18) | CIED/vascular grafts infections (n = 12) | p value |
|---|---|---|---|---|---|---|
| Actual dalbavancin treatment | ||||||
| Antimicrobials | 1160 (1160–3481) | 1160 (1160–1160) | 2707 (2320–4641) | 1160 (1160–3481) | 3481 (1160–3481) | 0.017 |
| Infusion sets and accessories | 0 (0–37) | – | 37 (18–37) | 37 (0–37) | 37 (0–37) | 0.018 |
| Hospital accommodationa | 0 (0–375) | 164 (0–1735) | 0 (0–374) | 0 (0–374) | – | 0.109 |
| Total cost of dalbavancin treatment | 1178 (1160–3518) | 1160 (1160–1160) | 2744 (2339–4679) | 1197 (1160–3518) | 3518 (1160–3518) | 0.013 |
| Hypothetical continuation of in-hospital standard treatment | ||||||
| Antimicrobials | 1690 (1642–5019) | 1545 (287–1673) | 5302 (3346–6692) | 4296 (1673––4973) | 1673 (1642––5019) | 0.009 |
| Infusion sets and accessories | 23 (19–56) | 19 (18–19) | 43 (36–73) | 31 (19–57) | 55 (18–57) | 0.031 |
| Hospital accommodation | 8596 (5502–16,506) | 5502 (5117–7469) | 11,642 (10,108–13,216) | 6629 (5502–16,506) | 18,963 (7742 –23,226) | 0.001 |
| Total cost of hypothetical continuation of standard treatment | 9660 (7135–20,845) | 6765 (5784–8346) | 16,094 (14,328–19,925) | 8328 (7149–21,538) | 23,603 (9419–27,884) | 0.002 |
| Costs saved by switching to dalbavancin | ||||||
| Antimicrobials | 530 (409–1537) | 385 (− 872 to − 530) | 2050 (1025–2076) | 512 (482–1288) | 1144 (512–1537) | 0.005 |
| Infusion sets and accessories | 19 (18–20) | 18 (18–19) | 27 (4.56–35) | 19 (17–21) | 18 (18–20) | 0.951 |
| Hospital accommodation | 7846 (5502–15,756) | 5383 (3129–6719) | 11,156 (10,108–13,216) | 6629 (5502–15,756) | 18,963 (7742–23,226) | 0.001 |
| Total cost saved | 8259 (5644–17,270) | 5034 (3647–6590) | 12,882 (11,970–15,246) | 7131 (5644–17,270) | 20,084 (8259–24,366) | 0.007 |
Values are expressed as € per patient, median (IQR)
ABSSSIs acute bacterial skin and skin structure infections, CIED cardiac implantable electronic device, IQR interquartile range
aThirty-six patients were discharged on the same day of the first dalbavancin dose; median hospitalization length-of-stay after the switch to dalbavancin in the remaining 14 subjects was 2 days (range 1–11)